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ABSTRACT 
Introduction: The United Kingdom (UK) Strategy for Rare Diseases places a strong emphasis on the need 
to empower people affected in order to improve diagnosis, intervention, and coordination of care. An 
important group to consider are families with children with a rare chromosome disorder (RCD). This study 
reports on families’ experiences of diagnosis and counselling, highlights changes over ten years, and 
identifies recommendations for improvement. 
Methods: Two national surveys were undertaken by Unique (Rare Chromosome Disorder Support Group) to 
compare families’ experiences over the decade prior to the launch of the strategy.  Questionnaires explored 
seven stages of the care pathway from pre-testing, to diagnosis, genetics consultation, follow-up and then 
sign-posting to peer support, plus measurement of perceived service quality. 
Results: Response rates were: 36.4% in 2003 (583 families) and 53.6% in 2013 (575 families). Mean age of 
respondents was 42.3 years and 43.0 years respectively. Analysis of responses identified 28 user-identified 
areas for service improvement for families affected by RCDs.  Only 12/28 are currently incorporated in 
service specifications. 
Conclusions: Identification of user-led, evidence-based recommendations can empower those affected by 
RCDs and enable professionals to co-design improved services through involvement of family support 
groups.  A series of further surveys is planned. 
Key Words: Families’ Experiences, Clinical Genetics Services, Rare Chromosome Disorders, National 
Surveys, Patient Reported Outcomes (PROs), Evidence-Based Clinical Guidelines. 
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1.  INTRODUCTION 1 
2 
The United Kingdom (UK) Strategy for Rare Diseases places a strong emphasis on empowering those affected 3 
by rare diseases in order to improve diagnosis, intervention, and coordination of care in genetics services 1.  4 
Although the strategy was published in late 2013, implementation plans are still being developed for England 5 
in 2017 with a view to being fully actioned in 2020.  It is acknowledged that this will require “strengthening the 6 
mechanisms and opportunities for meaningful and sustained patient involvement in rare disease service 7 
provision”. 8 
9 
An important and challenging group to consider when involving those affected by rare diseases will be children 10 
with a rare chromosome disorder (RCD).  In the UK, it is estimated that at least 300-500 children are born 11 
every year with one of a range of RCDs, widely spread geographically 2.  In comparison to more common and 12 
well-studied chromosome disorders like Down syndrome, there is far less information available on the natural 13 
history or prognosis for these rare diseases (<5 per 10,000 births) 3.  Their extreme rarity means RCD cases 14 
can be particularly challenging for genetics services because, in addition to communicating a laboratory 15 
diagnosis, professionals also need to support families who frequently experience severe distress combined 16 
with high levels of uncertainty 4.  In such a situation, service providers must ensure that parents understand 17 
the diagnosis, help families identify effective coping strategies, and address the lack of available evidence 5 6.  18 
To date, little is known about the experiences of these families, or the degree to which Clinical Genetics 19 
Services currently meet their needs.  This is an important gap, since the UK strategy emphasises that 20 
successful implementation will require “recognising patient groups as key partners” to develop care pathways 21 
that incorporate “best practice from the user perspective” 1. 22 
23 
Patient-reported outcomes for Clinical Genetics Services are still in their infancy 7.  Over the last decade some 24 
developments have occurred, largely driven by the extension of clinical genetic services from diagnosing 25 
conditions that are exclusively genetic in nature to investigating genetic components for more common 26 
diseases 8, with increased knowledge about the contribution of genetic factors to a range of common diseases 27 
9.  Comprehensive data are not yet available for RCDs although it is anticipated that, in time, the new National 28 
Congenital Anomaly and Rare Disease Registration Service established by Public Health England will fill this 29 
gap in knowledge 10, with projects such as the Sanger DECIPHER database 11 and the Unique 30 
registry/database and information guide service 12 also contributing to an improved knowledge base.  31 
Currently, there is no European Reference Network (ERN) specific to RCDs despite pan-European efforts to 32 
create one.  However, the UK-led ERN-Ithaca for intellectual disability and congenital malformations will 33 
include RCDs with family support group representation and promises to be a channel through which the 34 
experiences of RCD families can be improved. 35 
36 
For chromosome disorders, technological developments such as the introduction of microarray-based 37 
comparative genomic hybridisation (microarray analysis) techniques have meant that chromosome 38 
abnormalities which were formerly too small to be detected by conventional karyotyping can now be identified.  39 
Although this has significantly improved sensitivity for detection of clinically relevant genomic imbalances, it 40 
has also increased the need for comprehensive genetic counselling to ensure accurate clinical interpretation 41 
13.  In the case of RCDs, clinical interpretation will still face a high level of uncertainty about each affected 42 
child’s health, potential cognitive development, and life span even after there is a definitive diagnosis 14-16. 43 
44 
In this paper, we present the findings of two large scale surveys which investigated the experiences of UK 45 
families who have a child with a RCD over the period 2003 – 2013.  We examined the entire care pathway 46 
including provision of pre-test information, diagnosis of RCD, genetic counselling, provision of follow-up 47 
information and ongoing support.  Analysis of responses at different time-points is used to reveal trends and 48 
changes over time.  The findings should hopefully enable best practice from the user perspective to be more 49 
effectively integrated into the implementation phase of the UK Strategy for Rare Diseases. 50 
51 
52 
1.1  Objectives 53 
54 
The study had three main objectives: 55 
56 
1. to examine RCD families’ experiences along the entire care pathway; 57 
2. to compare differences over ten years and identify positive or negative changes over time; and 58 
3. to recommend improvements to service provision for this important patient group. 59 
60 
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2.  METHODS 61 
62 
2.1  Survey Overview 63 
64 
Two surveys were undertaken using a detailed questionnaire designed by Unique, a UK-based Rare 65 
Chromosome Disorder Support Group.  The group has over 15,300 member families, representing over 17,000 66 
individuals affected by RCDs, in over 100 countries worldwide, with around 1500 new families registering 67 
annually 17.  The process for designing the questionnaire is described in Supplementary file 1.  The first survey 68 
was undertaken in March 2003 and the second in May 2013.  Both surveys were limited to members with at 69 
least one surviving child with RCD and a valid UK address, and the 2013 survey to UK families who had joined 70 
the group since March 2003.  Both were identical, except for the addition of some questions in 2013 relevant 71 
to the introduction of microarray analysis 18.  The layout of questionnaires was designed to minimise the 72 
possibility of systematic missing responses.  Questionnaires in 2003 were pre-printed and posted out to 73 
families while questionnaires in 2013 could be completed online or printed off and returned by post; responses 74 
were anonymous.  The initial invitation in 2013 was followed by two email reminders. 75 
76 
2.2  Questionnaire Content 77 
78 
Questionnaires collected background information on the family.  Respondents were then asked about their 79 
experiences during different stages of the patient journey (see Table 1).  A separate question asked families 80 
to rate the quality of the overall service from a user perspective in terms of the overall service received on a 81 
ten-point Likert scale ranging from 1 (worst) to 10 (best), and how helpful overall the genetics counselling 82 
service has been since their first appointment (4 categories ranging from ‘not very helpful’ to ‘very helpful’).  83 
Finally, respondents were invited to give free text descriptions of their experiences of diagnosis and genetic 84 
counselling.  A copy of the 2003 postal questionnaire is provided in Supplementary file 2. 85 
86 
2.3 Data Analysis 87 
88 
Numerical data were summarised using mean and SD or median and range, depending on data distribution.  89 
Analysis was based on completed question responses.  There was no imputation of missing data, although 90 
we investigated to assess as far as is possible that missing data were missing completely at random.  Certain 91 
descriptive variables with multiple response categories were dichotomized before analysis e.g. whether person 92 
communicating diagnosis was ‘genetics professional’ or ‘non-genetics professional’, whether the method of 93 
communicating was ‘in person face-to-face’ or ‘indirect by phone, letter etc.’.  For comparison of baseline and 94 
2013 responses, chi-square tests were performed for categorical variables and t-tests or Mann–Whitney U 95 
tests for continuous variables.  95% confidence intervals were estimated together with the significance level 96 
of observed differences. In addition, some 2013 survey responses were analysed separately for cases 97 
diagnosed before and after the introduction of microarray tests in 2008.  Stata (version 13) was used for all 98 
analyses.  Statistical significance was set at p=0.001 level. 99 
100 
2.4  Recommended Improvements 101 
102 
A list of recommended improvements was compiled by knowledgeable family members with direct personal 103 
experience of RCD, as well as a clinical geneticist and genetics laboratory scientists.  Recommendations 104 
were based on analysis of data extracted from the questionnaire responses (with detailed examination of 105 
levels, significant changes or lack of a significant difference over time). 106 
107 
108 
3.  RESULTS 109 
110 
3.1  Respondents  111 
A total of 583/1600 families responded to the 2003 survey (36.4% response rate).  In 2013, of 584 112 
responses received; 9 families not resident in the UK were excluded, leaving a total of 575/1072 113 
questionnaires for analysis (53.6 % response rates). 114 
115 
Respondent characteristics were similar in the two groups.  Mean age was 42.3 years in 2003 and 43.0 years 116 
in 2013.  Questionnaires were mainly completed by mothers, although this proportion fell over time from 92.3% 117 
to 85.9% in 2013.  The majority described themselves as White British/ White European, although ethnic 118 
minority respondents doubled over the period from 4.8% to 8.5%.  Most families had only one child with a 119 
RCD, with this figure rising over the ten years from 86.1% to 92.3%.  A small minority of families had lost a 120 
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child with a RCD at or after birth; this figure had reduced over time from 6.5% in 2003 to 2.2% in the 2013 121 
sample. 122 
123 
3.2  Rating of service received 124 
When asked how helpful the genetics counselling service had been since their first appointment, Figure 1a 125 
shows views were fairly evenly spread across the four categories ranging from ‘not very helpful’ to ‘very 126 
helpful’, although the most common response was ‘had no more contact’.  The percentage rating a service 127 
as ‘not very helpful’ did not alter over time; it was 18.7% (95% Confidence Interval (CI): 15.1 - 22.7) in 2003 128 
and 15.0% (95% CI: 11.6 - 19.0) in 2013 (p=0.161). 129 
130 
When asked to rate overall service quality on a ten-point scale, average scores rose from 6.37 [SD 2.63] in 131 
2003 to 7.00 [SD 2.52] in 2013.  Figure 1b shows mean scores for different professional groups (i.e. genetics 132 
doctors, genetics counsellors, and genetics nurses).  In 2013, scores were 7.1 (95% CI 6.9, 7.3), 6.5 (6.0, 7.1), 133 
and 6.6 (5.7, 7.5) respectively.  Therefore, using an unpaired t-test, the genetics doctors scored statistically 134 
significantly higher than the genetics counsellors.  Comparison of the genetics doctors with the nurses, and of 135 
the counsellors with nurses, were not statistically significant.  136 
137 
3.3  Families’ experiences over ten years 138 
Families’ experiences of services over time are presented in Table 2. 139 
140 
1: Pre-testing process: In 2003 only 70.7% (95% CI: 66.4 - 74.7) of families reported that they had been 141 
informed that their child's chromosomes were going to be tested.  In 2013, this figure was slightly higher at 142 
73.2% (95% CI: 68.6 - 77.5) but showed no significant improvement over the ten years (p=0.404). 143 
144 
2: Test result communication: In 2003, test results were far more likely to be communicated by a paediatrician 145 
(64.5% (95% CI: 60.3 - 68.5)) than a genetic specialist (23.8% (95% CI: 20.2 - 27.5)).  By 2013, results were 146 
almost equally likely to be communicated by a genetic specialist (49.0% (95% CI: 44.3 - 53.7)) or a 147 
paediatrician (45.0% (95% CI: 40.3 - 49.7)).  Results were rarely reported by other professionals e.g. GPs, 148 
genetic nurses, obstetricians, health visitors. 149 
150 
Table 2 indicates that, over the ten year period, it has become significantly less likely (p<0.001) that parents 151 
will be informed in person about their child’s chromosome disorder, although even in 2013 the majority still 152 
stated that they were told in person (62.7% (95% CI: 58.2, 67.1)) versus 76.1% (95% CI: 72.4 - 79.6) in 2003.  153 
During the same period, communication by telephone doubled from 12.2% (95% CI: 9.6 - 15.2) to 22.1% 154 
(95% CI: 18.4 - 26.1) in 2013, and by 50% for letters from 10.1% to 14.4%.  Similar trends, away from telling 155 
parents in person, are observable for both professional groups (i.e. paediatricians and genetic specialists). 156 
157 
Possibly linked to this trend, responses indicate a shift towards families receiving their test result at home.  158 
This has risen significantly (p<0.001) from 17.1% (95% CI: 14.0, 20.6) in 2003 to 27.1% (95% CI: 22.9, 31.7) 159 
in 2013.  At the same time, there has been an increase (p=0.006) in test results being communicated in a 160 
genetics centre from 8.7% (95% CI: 6.5 - 11.5) to 14.4% (95% CI: 11.1, 18.2); and a significant drop (p<0.001) 161 
in parents receiving information on the ward after birth or on the children’s ward (28.5% (95% CI: 24.6 - 32.5) 162 
vs. 14.7% (95% CI: 11.4 - 18.4).  Throughout, one in four families continued to receive their test results in a 163 
doctor’s surgery (26.7% vs. 23.6% in 2013) and one in ten in a child development centre (11.3% vs. 11.5%).  164 
The proportion who are told in private has not changed significantly (p=0.697) over this period; 80.2% (95% 165 
CI: 76.5 - 83.5) in 2003 and 81.1% (95% CI: 77.2 - 84.8) in 2013.  Services did not always ensure that 166 
support was available from a spouse/partner, relative or friend when imparting this life-changing information.  167 
In 2003, one quarter of respondents (23.1% (95% CI: 19.5 - 26.9)) were on their own when they received 168 
the diagnosis; rising slightly (p=0.082) to 28.0% (95% CI: 23.8 - 32.4)) in 2013.  In addition, 47.3% (95% CI: 169 
42.9 - 51.7)) said that their affected child had been present in 2003, and 46.1% (95% CI: 41.3 - 50.9)) in 170 
2013, indicating no significant change (p=0.710). 171 
172 
3: Referral to a genetic specialist: Table 2 shows that the proportion of families receiving genetic counselling 173 
has decreased slightly (p=0.031) from 58.4% (95% CI: 54.2 - 62.5)) in 2003 to 52.0% (95% CI: 47.7 - 56.2)) 174 
in 2013.  For families informed about their child's test result by a non-geneticist (i.e. paediatrician, GP etc.) 175 
likelihood of referral to a genetic specialist has not increased (p=0.322), with two out of ten not offered a 176 
referral; 22.3% (95% CI: 18.4 - 26.7)) in 2003 and 19.3% (95% CI: 14.9 - 24.2)) in 2013.  In families where 177 
a second child was diagnosed with an RCD, this figure remains similar (22.7% vs. 21.7% in 2013). 178 
179 
6 
Once referred, the waiting time for an appointment was over 3 months with a slight non-significant (p=0.105) 180 
increase over time; 95.7 days in 2003 (95% CI: 83.6 - 107.7)) and 115.0 days (95% CI: 94.4 - 135.7)) in 181 
2013.  For a medical geneticist the time has increased from 103.5 days to 172.1 days and for a genetic 182 
counsellor from 118 days to 199.1 days.  However, for genetic nurses waiting times have fallen from 118 days 183 
to 75.6 days.  In cases where a definitive diagnosis could not be made at the time of the appointment (15%), 184 
further tests are increasingly likely to be ordered; 43.1% of such cases in 2003 and 60.0% in 2013.  These 185 
further tests produce a change in the provisional diagnosis in one in ten cases (11.6% in 2003 and 9.9% in 186 
2013). 187 
188 
4: Conduct of genetic consultation: Table 2 shows that most respondents considered they had been informed 189 
of their child’s condition in a sensitive manner; with a slight rise (p=0.014) from 66.9% (95% CI: 62.6 - 70.9)) 190 
in 2003 to 74.1% (95% CI: 69.8 - 78.2)) in 2013.  There appear to be consistent differences between the 191 
perceived sensitivity of different professional groups; for genetic professionals, 81.6% in 2003 and 86.2% 192 
in 2013 were viewed as providing the information sensitively, 63.3% and 67.7% of paediatricians 193 
respectively, and 43.8% vs. 44.0% of other clinicians. 194 
195 
The conduct of consultations was explored in some detail.  Although genetic specialists always introduced 196 
themselves (>98% consultations), families were not always told how long the consultation would take 197 
(45.6% vs. 38.1% in 2013) or asked what information they already had (24.7% vs. 24.3% in 2013 not asked), 198 
and half were not asked how detailed they would like information provided to be (56.5% vs. 54.4% in 2013).  199 
Almost half of respondents thought the genetic specialist did not seem to know about them and their family 200 
(49.1% vs. 42.3% in 2013), one in five said that a family genetic history was not taken (20.7% vs. 21.0% in 201 
2013), and one third said that there had been no physical examination of their child (37.4% vs. 31.9% in 202 
2013).  The risk of having another baby with an RCD was not always explained, with evidence of a decline 203 
over time and variation between professionals; medical geneticists (11.8% vs. 20.0% in 2013 did not 204 
explain), genetic counsellors (19.0% vs. 32.1%), and genetic nurses (27.8% vs. 30.0%).  205 
206 
Provision of a written summary following the genetic consultation is considered to be good practice 19.  In 2003, 207 
written summaries were provided by 69.0% of medical geneticists, 50.7% of genetics counsellor and 43.8% of 208 
genetics nurses.  By 2013, although figures had risen to 81.0%, 65.3% and 65.4% respectively, they were still 209 
not provided for all as routine practice.  On average, families had to wait one month to receive a summary, 210 
but some waited as long as 6 months; in 2013 longer delays were reported.  The written information provided 211 
was considered easy to understand by almost all recipients (93.0% in both 2003 and 2013). 212 
213 
5: Genetic and clinical information provision: Although most respondents could understand the information 214 
provided (92.7% in 2003 vs. 89.7% in 2013), the majority considered they had not been given enough 215 
information about their child’s condition.  Table 2 shows this did not change significantly (p=0.093) over 216 
time; 69.4% (95% CI: 65.2 - 73.4) in 2003 and 64.3% (95% CI: 59.6 - 68.8) in 2013.  Responses were not 217 
affected by the introduction of microarray analysis, with 66.4% pre-2008 and 61.4% post-microarrays 218 
reporting a need for more information.  In terms of the content of the information provided, although the 219 
majority of families were told which chromosome numbers were involved this has not increased significantly 220 
(p=0.067); 78.5% (95% CI: 74.6 - 82.0) were told in 2003 and 83.3% (95% CI: 79.4 - 86.7) in 2013.  However, 221 
explanation of the type of chromosome disorder in a clear and understandable way has improved 222 
significantly (p<0.001) rising from 57.2% (95% CI: 52.8 - 61.6) in 2003 to 75.1% (95% CI: 70.7 - 79.1) in 223 
2013.  Similarly, although a significant proportion of families are not given the karyotype, this has decreased 224 
over time (44.4% in 2003 falling to 34.0% in 2013). 225 
226 
Virtually all respondents (95%) said they would have liked a copy of the genetics laboratory report.  Although 227 
this was not provided in the majority of cases, there is evidence that families are increasingly likely to be 228 
given a copy.  In 2003, 71.1% were not given a copy, compared to only 48.6% in 2013.  However, when 229 
laboratory reports were provided, only half included a suitable explanation of the medical or technical terms 230 
used, with no evidence of improvement over time (52.2% in 2003 vs. 50.2% in 2013). 231 
232 
In terms of the clinical prognosis, nearly one in three respondents said that they were not told the possible 233 
effects on their child of the chromosomal abnormality (30.1% vs. 28.7% in 2013). In cases where this is 234 
provided, accuracy appears to have improved over time e.g. for genetic nurses from 68.3% to 75.7% 235 
considered accurate in 2013. 236 
237 
6: Genetic service follow-up: Although most families were offered a further meeting to discuss their child’s 238 
chromosome disorder, one third reported that they were not.  There was a slight but non-significant (p=0.158) 239 
7 
improvement over time.  In 2003, 35.2% (95% CI: 31.1 - 39.5) were not offered a further meeting, falling to 240 
30.9% (95% CI: 26.6 - 35.5) in 2013.  Linked to this, only a minority of families said they were told how the 241 
genetic counselling service could help them in the future; 28.9% in 2003 and 31.0% in 2013. 242 
243 
7: Signposting to peer support: Signposting of families by all specialists to some form of peer support group 244 
has risen significantly, from 34.8% of families in 2003 to 58.7% in 2013.  Respondents were increasingly 245 
likely to be signposted to Unique (26% in 2003 rising to 67% in 2013).  Only a small number of respondents 246 
stated that the genetic specialist tried to put them off contacting other affected families (7.3% in 2003 and 247 
3.9% in 2013).  Nevertheless, very few respondents (7% in both time periods) reported that they were 248 
offered any help to contact other RCD families. 249 
250 
3.4 Recommended improvements identified 251 
252 
Table 3 lists the recommended improvements identified by experts based on survey responses.  The 253 
penultimate column identifies which are included in the NHS England service specification for organisations 254 
funded to provide specialised medical genetics services 20.  This indicates that 12 out of 28 recommendations 255 
identified by the present study are already included in service specifications.  However, aspects which are 256 
missing include: a) education of non-clinical professionals; b) recommended speed of testing; c) six practical 257 
recommendations for communication of test results; d) need to indicate waiting time for referral to a genetics 258 
expert; e) five specific recommendations for conduct of consultation with genetics expert.  For section f), all 259 
recommendations identified by the current study are included in the service specification.  The final column 260 
shows levels achieved as reported by respondents for selected recommendations included in the service 261 
specification.  These range from 36% to 80%. 262 
263 
4.  DISCUSSION 264 
265 
The necessity for patient reported outcomes (PROs) in clinical genetics services has been identified in a recent 266 
review 7.  However, provision of services to families who have a child with a RCD is acknowledged to be 267 
exceptionally challenging 4-6.  There is also limited research evidence.  A review of research into clinical 268 
genetics services and the patient perspective which identified 102 articles 21 found only one focused on these 269 
families 3.  The recommendations identified in the current study are novel because they are based on the real-270 
life experiences of over one thousand families living with RCDs.  As PROs become more important in 271 
performance management and funding of health services 7, sustained capture of the experiences of such 272 
families will be a key challenge 1.  Although a recommendation for ‘sustained patient involvement in rare 273 
disease service provision’ was embedded in the UK strategy for rare diseases, the overall strategy 274 
implementation plan for England has only recently been announced 22.  275 
276 
The large scale surveys reported here show that, although families’ rating of service quality has improved 277 
over time, key aspects of the ‘patient journey’ have not and require improvement.  Although agreement on 278 
key PROs for genetic services is generally acknowledged to be challenging for RCD cases 7 23, our surveys 279 
do highlight a number of simple improvements which might be easily introduced and which are indicated 280 
elsewhere.  For example, a review of guidelines from 18 organisations in six countries on communication of 281 
genetic information to families concluded that there was a significant gap in terms of the professional’s role in 282 
assisting clients to find options for continued support 24.  This is a key finding identified from our surveys.  Our 283 
results also echo evidence from US research which found that parents of children with RCDs were largely 284 
disappointed in the counselling they received, although this was a small-scale study 3.   285 
286 
Although international guidelines for clinical genetics professionals largely cover the professional-client 287 
relationship, including respect for the client, maintaining confidentiality, and enabling clients to make informed 288 
independent decisions 25 26, they do not include more practical PROs such as those reported in the present 289 
study.  Other recommendations, such as those produced by Rare Disease UK (a project of the charity Genetic 290 
Alliance UK) mostly concentrate on higher level activities (e.g. commissioning and planning of services for rare 291 
diseases) with some general recommendations to improve information and support 27.  More recent 292 
recommendations for reporting the results of diagnostic genetic tests primarily focus on providing patients with 293 
information on how to manage their own condition, something which is less relevant for families of children 294 
with RCDs 28.  However, the most recent service specification for organisations providing specialised NHS 295 
medical genetics services does include some, but not all, of the recommendations identified in the present 296 
study 20. 297 
298 
8 
Meanwhile, international evidence has emerged of large variations in clinical genetics practice, leading to an 299 
increased interest in defining the quality of services and improving delivery models 29-31.  Core competences 300 
and a code of practice have been produced for European health professionals 19 32, based on research by 301 
Skirton et al. 33 and approved by the European Society of Human Genetics 34.  To date such recommendations 302 
are based on the subjective views of professionals, rather than evidence-based, data on user experience.  303 
More recently, the US National Society of Genetic Counselors launched a series of new Evidence-Based 304 
Clinical Practice Guidelines although up to now these do not include RCDs, only Fragile X Syndrome and 305 
Down Syndrome. (http://www.nsgc.org/practiceguidelines). 306 
307 
Service quality for RCD cases will inevitably be influenced by the availability of genetic specialist expertise.  In 308 
this respect, the UK appears to be fortunate, with a higher number of genetic counsellors/nurses per million 309 
population than other European countries 31.  The existence of a long-established Rare Chromosome Disorder 310 
Support Group also differentiates the UK from other countries.  As the rates of RCD diagnoses rise 311 
significantly, thanks to wider use of microarray analyses and the anticipated introduction of next generation 312 
DNA sequencing into routine clinical practice, combined with the fact that RCD cases are inevitable 313 
geographically widespread, the role of non-geneticist clinicians will inevitably continue at various stages of the 314 
patient journey, reinforcing the need for common guidelines, multidisciplinary teamwork, audit checklists, 315 
training and coordinated care pathways 35 36 37. 316 
317 
We recognise that the genetic and genomic testing and service landscape in the UK is also developing at a 318 
tremendous pace, not least because of the 100,000 Genomes project 38, the creation of 13 Genomic Medicine 319 
Centres across the UK 39, the Genomics England Clinical Interpretation Partnerships (GeCIP), designed to 320 
improve the accuracy and reliability of information fed back to patients 38; and a drive by Health Education 321 
England to educate non-genetics healthcare and other professionals in genomic medicine 40.  It is therefore 322 
imperative that the value of the expertise of UK families affected by RCDs is not lost in the rapid pace of 323 
developments in genomics per se for identifying current and future needs.  Although patients' and 324 
professionals' views may differ, there does appear to be a level of consensus on important domains such as: 325 
decision-making, knowledge of the genetic condition, perceived personal control, risk perception, diagnostic 326 
accuracy, and satisfaction/ quality of life 41.  Also, since clinical genetics services in the UK are currently 327 
delivered through a network of 23 centres, this network could facilitate the introduction of a coordinated 328 
strategy to support these families, although there is currently no designated centre of excellence specific to 329 
RCDs to take the lead.  It is possible that an holistic RCD-specific service might be introduced by the newly-330 
emerging rare disease centres, such as those in Birmingham 42 and London 43.   331 
332 
Our study inevitably has a number of limitations that should be borne in mind when considering the findings 333 
and subsequent recommendations.  Firstly, some bias in responses is likely as participants were recruited 334 
from a specialist support group and therefore respondents may be different from other UK families with an 335 
RCD child.  Secondly, it is possible that parents in Unique may be more knowledgeable because they are part 336 
of a well-established support group and have higher expectations (e.g. in terms of the information required) 337 
than people who do not belong to such an organisation.  Finally, there may be recall inaccuracy since, in some 338 
instances, the survey requested information from families sometime after the event.  339 
340 
Conclusions & Recommendations: 341 
These surveys of Unique members address the lack of data on genetic diagnosis and counselling care 342 
pathways experienced by families of children with RCDs.  Recommendations are offered in the spirit of 343 
constructive collaboration to assist clinicians to best meet the needs of patients and their families 20.  The 344 
findings set baseline data for the experiences of families in 2003 and 2013.  The intention is to repeat the 345 
surveys in 2018/2019 to gather patient-reported experiences as the new streamlined genetics service 346 
configuration is rolled out across the UK, and then again in 2021/2022 when new genetics services and 347 
implementation plans for the rare disease strategy are well embedded in the UK service provision.  We 348 
consider that establishment of this form of longer term overview of user experience is particularly important, 349 
not least because diagnoses and genetic counselling are likely to be increasingly provided by non-geneticist 350 
clinicians. 351 
352 
353 
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